FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Poll|November 14, 2013
The 23-Valent Pneumoccocal (Pneumovax) Vaccine: For Which Patients?
Author(s)Terry Brenneman, MD
For which of these patients would you give the 23-valent pneumoccocal vaccine?
Advertisement
Which of the following should get the 23-valent pneumoccocal (Pneumovax) vaccine per the Advisory Committee on Immunization Practices (ACIP) guidelines?
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
2
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
3
Type 2 Diabetes, Genetic Risk Linked to MASLD Cirrhosis Before Age 50
4
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
5